Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.

Details

Serval ID
serval:BIB_4469142B747F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
Journal
The Lancet. Neurology
Author(s)
Frisoni G.B., Boccardi M., Barkhof F., Blennow K., Cappa S., Chiotis K., Démonet J.F., Garibotto V., Giannakopoulos P., Gietl A., Hansson O., Herholz K., Jack C.R., Nobili F., Nordberg A., Snyder H.M., Ten Kate M., Varrone A., Albanese E., Becker S., Bossuyt P., Carrillo M.C., Cerami C., Dubois B., Gallo V., Giacobini E., Gold G., Hurst S., Lönneborg A., Lovblad K.O., Mattsson N., Molinuevo J.L., Monsch A.U., Mosimann U., Padovani A., Picco A., Porteri C., Ratib O., Saint-Aubert L., Scerri C., Scheltens P., Schott J.M., Sonni I., Teipel S., Vineis P., Visser P.J., Yasui Y., Winblad B.
ISSN
1474-4465 (Electronic)
ISSN-L
1474-4422
Publication state
Published
Issued date
08/2017
Peer-reviewed
Oui
Volume
16
Number
8
Pages
661-676
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The diagnosis of Alzheimer's disease can be improved by the use of biological measures. Biomarkers of functional impairment, neuronal loss, and protein deposition that can be assessed by neuroimaging (ie, MRI and PET) or CSF analysis are increasingly being used to diagnose Alzheimer's disease in research studies and specialist clinical settings. However, the validation of the clinical usefulness of these biomarkers is incomplete, and that is hampering reimbursement for these tests by health insurance providers, their widespread clinical implementation, and improvements in quality of health care. We have developed a strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers. Sufficient evidence of analytical validity (phase 1 of a structured framework adapted from oncology) is available for all biomarkers, but their clinical validity (phases 2 and 3) and clinical utility (phases 4 and 5) are incomplete. To complete these phases, research priorities include the standardisation of the readout of these assays and thresholds for normality, the evaluation of their performance in detecting early disease, the development of diagnostic algorithms comprising combinations of biomarkers, and the development of clinical guidelines for the use of biomarkers in qualified memory clinics.

Keywords
Alzheimer Disease/diagnosis, Biomarkers, Early Diagnosis, Humans, Validation Studies as Topic
Pubmed
Web of science
Create date
15/08/2017 11:24
Last modification date
20/08/2019 13:48
Usage data